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Immune thrombocytopenic 
purpura 
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Incidence 
• Peak prevalence in adults occurs aged 20-50 
years,  in children aged 2-4 years. 
• ITP is estimated to affect approximately 
3.3/100,000 adults/year and between 1.9 and 
6.4/100,000 children/year. 
• ITP affects people of both sexes and all ages—
there is no typical ITP patient. 
• Adult-onset ITP was once believed to be a 
disease largely afflicting young women 
Definition  
• Immune thrombocytopenic purpura (ITP) is an autoimmune disorder 
characterized by accelerated platelet destruction and suboptimal platelet 
production that leads to reduced peripheral blood platelet counts 
• "Idiopathic" means the cause is unknown.  
• "Thrombocytopenia" means a decreased number of platelets in the blood.  
• "Purpura" refers to the purple discoloring of the skin, as with a bruise. 
• The normal platelet level in adults is between 150,000 and 450,000/mm3. 
Types of immune thrombocytopenia 
1.Primary ITP 
2.Secondary ITP: 
• HIV 
• Hepatitis C 
• Helicobacter pylori  
• Immunodeficiencies 
• Evans' syndrome 
• Systemic lupus erythematosus 
• Lymphoproliferative disorders 
• Vaccine exposure 
• Drug-induced 
Pathogenesis  
• The famous Harrington–Hollingsworth Experiment established the 
immune pathogenesis of ITP. The coating of platelets with IgG 
renders them susceptible to opsonization and phagocytosis by 
splenic macrophages.  
• In many cases, the cause is not actually idiopathic but autoimmune, 
with antibodies against platelets being detected in approximately 
60% of patients.  
• Most often these antibodies are against platelet membrane 
glycoproteins IIb-IIIa or Ib-IX, and are of the IgG type.  
• The IgG autoantibodies are also thought to damage 
megakaryocytes, the precursor cells to platelets, but this is thought 
to contribute only slightly to the decrease in platelet numbers.  
• Recent evidence suggests that the stimulus for autoantibody 
production in ITP is due to abnormal T helper cells reacting with 
platelet antigens on the surface of antigen presenting cells.  
• This important finding suggests that therapies directed towards T 
cells may be effective in treating ITP. 
http://www.ejournalofdentistry.com/articles/e-JOD7B695FBBA5-
7D6C-46E7-98FF-F607C900EEBC.pdf 
Pathogenesis  
ITP is known to be associated with both: increased 
platelet destruction and impaired platelet production 
http://www.nplate.com/patient/understanding-itp/causes-itp.html 
Pathogenesis  
Effects of ITP on platelet production and destruction 
http://www.itpvillage.com/html/hcp/library-mechanisms-of-disease.aspx 
Pathogenesis  
Antibody-coated platelets are recognized by macrophages 
primarily in the spleen leading to their destruction 
http://www.ebmt.org/Contents/Resources/Library/Resourcesfornurses/Doc
uments/ITP%20Handbook.PDF 
Pathogenesis 
1. Increased platelet destruction is caused by autoantibody binding to 
platelets. 
2. Increased endogenous thrombopoietin (eTPO) clearance results in 
reduced eTPO levels. Increased platelet destruction leads to increased 
TPO clearance, resulting in less TPO available to stimulate platelet 
production. 
3.  Megakaryocytes may be damaged by antibodies, making them less 
productive than normal. 
4.  Suboptimal platelet production results from damaged megakaryocytes 
and reduced eTPO levels. 
Recommended ITP classification  
from 
“International Consensus report on ITP investigation” 
and management of primary ITP” 2009 
http://www.ihtc.org/wp-
content/uploads/2010/05/Final%20BT%20Spring%202010%20PRINT.pdf 
The  platelet count is a marker for the 
risk of serious bleeding 
• Counts below 20,000/mm3 increase the risk of spontaneous bleeding  
• Major bleeding, including spontaneous intracerebral hemorrhage, occurs predominantly in 
patients with platelet counts less than 20 000 × 109/L, generally less than 10 000 × 109/L. 
• Patients typically present with petechiae or purpura that develop over several days 
accompanied by platelet counts less than 20 000 × 109/L 
• Severe cutaneous bleeding, prolonged epistaxis, gingival bleeding, overt hematuria, or 
menorrhagia may develop at platelet counts less than 10 000 × 109/L. 
• Those with platelet counts between 30 000 and 50 000 × 109/L may note easy bruising, 
whereas platelet counts above 50 000 × 109/L are usually discovered incidentally. 
• Rarely, do patients present with bleeding disproportionate to the platelet count because of 
antibody-induced platelet dysfunction. 
Symptoms 


Petechiae and Purpura 
http://www.getwellnatural.com/idiopathic-
thrombocytopenic-purpura-itp.aspx 
http://www.ispub.com/journal/the-internet-journal-of-hematology/volume-6-
number-2/corticosteroid-resistant-idiopathic-thrombocytopenic-purpura-case-report-
and-literature-review.html 
Petechial hemorrhages on the palate 
http://d-l.com.ua/pics/tabl/Tretjakova_2(9)_2_2011.jpg 
Ecchymoses in Immune-Mediated Thrombocytopenic Purpura 
Ecchymoses in Immune-Mediated Thrombocytopenic Purpura 
If you see someone with this ugly-looking bleeding in gums, and ecchymosis, you 
really need to get moving on a treatment because this could be a warning of 
potential intercranial hemorrhage, which we always worry about.  
http://www.hopkinsarthritis.org/physician-corner/rheumatology-
rounds/round-8-autoimmune-thrombocytopenia/ 
Dignostics  
 
 
Recommended diagnostic approaches 
for ITP 
The Peripheral Blood Smear in ITP 
• Consistent with the diagnosis of ITP 
1. Thrombocytopenia. Platelets are normal in size or may 
appear larger than normal, but consistently giant platelets 
(approaching the size of red blood cells) should be absent. 
2. Normal red blood cell morphology. 
3. Normal white blood morphology. 
• Not consistent with the diagnosis of ITP 
1. Predominant giant platelets. 
2. Red blood cell poikilocytosis, schistocfles, 
polychromatophilia (unless response to bleeding), 
macrocytes, nucleated red blood cells. 
3. Leukocytosis or leukopenia, with immature or abnormal 
cells 
(although atypical lymphocytes and eosinophilia may occur in 
children with ITPI). 
Upper panel: normal platelet count. 
Lower panel: severe thrombocytopenia.  
Bone marrow aspirate- megacaryocyte 
Microscopic Features: 
•  10-30x larger than a mature RBC (Largest hematopoeitic cell) 
•  Lower nuclear to cytoplasmic ratio because of increased cytoplasm 
•  Multilobated Nucleus (2-8 lobes on top of each other) with mature 
chromatin (clumped) 
•  Nucleoli are absent 
•  Cytoplasm is abundant and light blue and usually lacks granules 
http://hematologyoutlines.com/atlas_topics/5
6.html 
Indications for bone marrow aspirate 
in ITP 
Bone marrow aspiration is used to exclude other 
diagnoses and is indicated in: 
•  older patients (particularly those over 60 years of 
age to exclude myelodysplastic syndrome) 
• in those with an atypical presentation (e.g. 
abnormalities observed on peripheral blood 
smear suggestive of other haematological 
disorders) 
• in those with a poor response to first-line therapy 
and  
• in those being considered for splenectomy. 
ITP - bone marrow aspirate 
• The typical finding in a bone marrow biopsy of a 
patient with ITP is an increase in megakaryocytes 
without other concomitant abnormalities. 
http://imagebank.hematology.org/AssetDetail.
aspx?AssetID=3613&AssetType=Asset 
A high-power view shows that some of the 
megakaryocytes appear relatively immature 
with hypolobulated nuclei and hypogranular 
cytoplasm. 
Treatment   

History of ITP treatment 

Algorithm of therapy of adult ITP 
Douglas B. Cines and James B. Bussel 
http://bloodjournal.hematologylibrary.org/content/106/7/2244.full#F1 
Emergency treatment 
• 1. i.v. methylprednisolone 500mg to 1g/day 
for 3 days 
• 2. IVIG 1g/kg/day for 2 consecutive days 
• 3. Platelet transfusion 
• Emergency splenectomy is considered if above 
measures fail to increase platelet count to safe 
level i.e. above 50x109/L.  
http://www.acadmed.org.my/view_file.cfm?fileid=256 
Prognosis 
• Adults are more likely to develop chronic ITP and spontaneous recovery is 
uncommon. 
• Many adult ITP patients, however, experience mild and stable disease 
requiring no treatment. 
• In contrast, ITP is usually acute in children, particularly in those under 10 
years of age, with recovery observed in the majority of cases even after 
several weeks to months of severe thrombocytopenia.  
• Around 80% of children will spontaneously recover within 6 months with 
or without receiving treatment. 
• Some 15–20% of children will, however, develop chronic ITP. 
• Among ITP patients who respond to therapy, mortality is similar to that of 
the general population. 
• Among those who do not respond within the first few years of receiving 
therapy there is a higher risk of morbidity and mortality. 
• Deaths are rare, but may be as high as 3% per year in refractory ITP 
patients and are usually related to intracranial haemorrhage or infection 
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